Yahoo · Jul 30, 2026
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
CS
NASDAQ · CSBR
Champions Oncology, Inc.
Healthcare · Biotechnology
$5.07
Down-$0.07 (-1.27%)
Updated Aug 15, 2026, 9:36 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 87.12M
- P/E ratio
- 29.81
- Dividend yield
- 0.00%
- 52-week range
- $4.88 – $7.00
- Volume
- 26.34K
- Avg. volume
- 19.79K
Price performance
CSBR price history
1M range · 21 trading sessions · Daily adjusted prices
CSBR closed at $5.07 after 21 trading sessions, down 17.37% for the selected period.
- Last close
- $5.07
- Period change
- -17.37%
- Period low
- $4.95
- Period high
- $6.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $5.02 | $5.37 | $4.94 | $5.065 | 26.34K |
| Aug 13, 2026 | $4.88 | $5.13 | $4.88 | $5.08 | 14.22K |
| Aug 12, 2026 | $4.89 | $5.09 | $4.89 | $4.95 | 5.68K |
| Aug 11, 2026 | $5.06 | $5.3892 | $4.88 | $4.99 | 16.14K |
| Aug 10, 2026 | $5.18 | $5.21 | $5.09 | $5.14 | 7.68K |
| Aug 7, 2026 | $5.00 | $5.27 | $5.00 | $5.19 | 4.79K |
| Aug 6, 2026 | $5.39 | $5.41 | $5.15 | $5.19 | 15.82K |
| Aug 5, 2026 | $5.37 | $5.40 | $5.20 | $5.30 | 14.57K |
| Aug 4, 2026 | $5.605 | $5.73 | $5.40 | $5.45 | 18.69K |
| Aug 3, 2026 | $5.26 | $5.76 | $5.26 | $5.76 | 2.93K |
| Jul 31, 2026 | $5.32 | $5.50 | $5.32 | $5.36 | 2.01K |
| Jul 30, 2026 | $5.30 | $5.4501 | $5.215 | $5.26 | 16.4K |
| Jul 29, 2026 | $5.3857 | $5.591 | $5.3857 | $5.46 | 11.56K |
| Jul 28, 2026 | $6.48 | $6.48 | $5.39 | $5.53 | 30.94K |
| Jul 27, 2026 | $6.10 | $6.15 | $6.06 | $6.06 | 8.29K |
| Jul 24, 2026 | $6.00 | $6.16 | $5.75 | $6.13 | 11.29K |
| Jul 23, 2026 | $5.71 | $6.00 | $5.71 | $6.00 | 1.41K |
| Jul 22, 2026 | $6.16 | $6.16 | $5.95 | $6.13 | 2.81K |
| Jul 21, 2026 | $6.10 | $6.13 | $6.10 | $6.10 | 977.7 |
| Jul 20, 2026 | $6.10 | $6.1499 | $6.10 | $6.10 | 2.13K |
| Jul 17, 2026 | $5.97 | $6.13 | $5.97 | $6.13 | 11.86K |
Latest CSBR news
The latest Smart Investors Daily articles mentioning CSBR.
Stock researchCompany · Overview
CSBR research
Overview
Company profile and research snapshot.
Company profile
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 12, 2025 | Craig-Hallum | Buy | — |
| Dec 12, 2024 | Craig-Hallum | Buy | — |
| Sep 12, 2024 | Craig-Hallum | Buy | — |
| Mar 13, 2024 | Craig-Hallum | Hold | — |
| Sep 22, 2023 | Roth MKM | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Jul 30, 2026
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...
Champions Oncology Inc (CSBR) achieved record annual revenue of $59.4 million and its fourth consecutive quarter of positive adjusted EBITDA, despite a significant drop in data-license revenue.
ChartMill · Jul 27, 2026
Champions Oncology (NASDAQ:CSBR) Surges on Earnings Beat and Margin Expansion, Highlighting Quality Growth Stock
Champions Oncology beat Q4 revenue estimates, posted record FY2026 sales of $59.4M, and saw margins improve; stock surged 9.7% after-hours.
SeekingAlpha · Jul 27, 2026
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
